Contract Research & Services
Clinical Trials

Clinical Trials News

View news from other Pharmaceutical sectors:
121-135 of 4294 results
Shield Therapeutics enrolls patients for phase 3 study of IDA drug Feraccru
Shield Therapeutics has completed enrollment of the Phase 3 AEGIS-CKD clinical trial of its European-marketed product, Feraccru.
Contract Research & Services > Clinical Trials > News
NanOlogy begins NanoPac’s phase 2 study to treat ovarian cancer
By PBR Staff Writer
NanOlogy has commenced the Phase 2 clinical study of intraperitoneally (IP) administered NanoPac (nanoparticle paclitaxel) to treat ovarian cancer.
Contract Research & Services > Clinical Trials > News
Bayer, Janssen halt phase III ESUS study of anticoagulant medicine Xarelto
By PBR Staff Writer
Bayer, along with its development partner Janssen Research & Development, has halted the phase III Navigate ESUS study of rivaroxaban (Xarelto), as it demonstrated comparable efficacy between treatment arms.
Contract Research & Services > Clinical Trials > News
Kadmon’s cGVHD drug gets FDA orphan drug designation
By PBR Staff Writer
Kadmon has secured orphan drug designation for its Rho-associated coiled-coil kinase (ROCK) inhibitor dubbed as KD025 from the US Food and Drug Administration (FDA) for treating chronic graft-versus-host disease (cGVHD).
Contract Research & Services > Clinical Trials > News
Anthem, HealthCore, Boehringer initiate pragmatic clinical trial to study people living with COPD in real-world setting
The first patients have now enrolled in AIRWISE, the world’s largest ever pragmatic clinical trial in chronic obstructive pulmonary disease (COPD) to study how commonly prescribed medicines may reduce the occurrence of exacerbations of COPD.
Contract Research & Services > Clinical Trials > News
Zika vaccine found safe, promising in first human trial
By PBR Staff Writer
A DNA-based Zika vaccine, dubbed GLS-5700, developed by a consortium led by Inovio Pharmaceuticals and GeneOne Life Science succeeded in a phase 1 clinical trial by producing anti-Zika response in humans.
Contract Research & Services > Clinical Trials > News
Motif Bio’s iclaprim meets primary endpoint in second phase 3 ABSSI trial
By PBR Staff Writer
UK-based Motif Bio reported that its skin disorder drug iclaprim has succeeded in a second phase 3 trial in patients with acute bacterial skin and skin structure infections (ABSSSI).
Contract Research & Services > Clinical Trials > News
10,000 to be tested in world’s first trial for universal flu vaccine
By PBR Staff Writer
NHS patients are taking part in a world-first trial for a universal flu vaccine supported by the National Institute for Health Research (NIHR) and delivered by the University of Oxford in Berkshire and Oxfordshire.
Contract Research & Services > Clinical Trials > News
Ablynx’s blood disease drug caplacizumab passes phase 3 aTTP trial
By PBR Staff Writer
Ablynx's blood disease drug caplacizumab succeeded in a phase 3 trial in patients with acquired thrombotic thrombocytopenic purpura (aTTP), a rare autoimmune blood clotting disorder.
Contract Research & Services > Clinical Trials > News
Zynerba cannabis-derived gel for Fragile X syndrome succeeds in phase 2 trial
By PBR Staff Writer
Zynerba Pharmaceuticals reported that its cannabis-derived gel to treat Fragile X syndrome (FXS) dubbed as ZYN002 has yielded positive results in a phase 2 trial.
Contract Research & Services > Clinical Trials > News
Tricida begins phase 3 study of TRC101 to treat metabolic acidosis associated with chronic kidney disease
Tricida announced that the first subject was enrolled in TRCA-301, a phase 3 study evaluating TRC101 in chronic kidney disease (CKD) patients with metabolic acidosis.
Contract Research & Services > Clinical Trials > News
MD Anderson Cancer Center, Pfizer Oncology partner to assess immuno-oncology combinations in blood cancers and solid tumors
The University of Texas MD Anderson Cancer Center and Pfizer have entered into a clinical collaboration to study novel combinations of three Pfizer investigational immuno-oncology therapies and other Pfizer agents in the treatment of various solid tumors and hematologic malignancies.
Contract Research & Services > Clinical Trials > News
Immune’s bertilimumab yields positive results in phase 2 bullous pemphigoid trial
By PBR Staff Writer
Immune Pharmaceuticals has reported that its ongoing phase 2 trial of bertilimumab in patients with moderate to severe bullous pemphigoid (BP) has yielded positive results.
Contract Research & Services > Clinical Trials > News
Bevespi Aerosphere demonstrates statistically significant improvement in lung function in patients with COPD
AstraZeneca has announced positive top-line results of the Phase III, PINNACLE 4 trial in which Bevespi Aerosphere (glycopyrronium and formoterol fumarate 14.4/9.6 µg) demonstrated a statistically significant improvement in lung function in patients with chronic obstructive pulmonary disease (COPD).
Contract Research & Services > Clinical Trials > News
Axovant’s Alzheimer's drug intepirdine fails in phase 3 trial
By PBR Staff Writer
Axovant Sciences has reported that intepirdine, its 5-ht6 antagonist to treat Alzheimer's disease (AD), failed to meet its co-primary efficacy endpoints in a phase 3 trial.
Contract Research & Services > Clinical Trials > News
121-135 of 4294 results